NGM Biopharmaceuticals

General Information


We are a clinical-stage biopharmaceutical company developing novel therapeutics based on our scientific understanding of key biological pathways underlying cardio-metabolic, liver, oncologic and ophthalmic diseases. These diseases are among the largest unmet medical needs globally and represent leading causes of morbidity and mortality and a significant burden for healthcare systems. Since the commencement of our operations in 2008, we have generated a robust portfolio of seven product candidates, five of which are in clinical testing. Our most advanced product candidate, NGM282, is wholly-owned and will enter Phase 2b development for the treatment of non-alcoholic steatohepatitis, or NASH, in the first quarter of 2019. In an ongoing Phase 2 clinical trial, NGM282 demonstrated the ability to rapidly improve NASH and reverse liver fibrosis at 12 weeks.

Employees: 153
Founded: 2007
Contact Information
Address 333 Oyster Point Boulevard, South San Francisco, CA 94080, US
Phone Number (650) 243-5555
Web Address
View Prospectus: NGM Biopharmaceuticals
Financial Information
Market Cap
Revenues $79.95 mil (last 12 months)
Net Income $-11.8 mil (last 12 months)
IPO Profile
Symbol NGM
Exchange NASDAQ
Shares (millions): 0.0
Price range $0.00 - $0.00
Est. $ Volume $75.0 mil
Manager / Joint Managers Goldman Sachs/ Citigroup/ Cowen
CO-Managers -
Expected To Trade:
Status: TBA
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change